Innovative strategies for effective paclitaxel delivery: Recent developments and prospects
Journal of Oncology Pharmacy Practice · 2024
DOI: 10.1177/10781552231208978 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Oncology Pharmacy Practice, 2024. Verfasst von Sławomir Wileński und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Technology, Nicolaus Copernicus University in Torun, Ludwik Rydygier Collegium Medicum, Bydgoszcz, Poland. Hauptthemen laut MEDLINE: Micelles, Antineoplastic Agents, Phytogenic. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 134 Literaturangaben.
Abstract (Originalsprache)
Purpose
Paclitaxel is an effective chemotherapeutic agent against a variety of cancer types. However, the clinical utility of paclitaxel is restricted by its poor solubility in water and high toxicity, resulting in low drug tolerance. These difficulties could be resolved by using suitable pharmacological carriers. Hence, it is essential to determine innovative methods of administering this effective medication to overcome paclitaxel's inherent limitations.
Methods
An extensive literature search was conducted using multiple electronic databases to identify relevant studies published.
Results
In this comprehensive analysis, many different paclitaxel delivery systems are covered and discussed, such as albumin-bound paclitaxel, polymeric micelles, paclitaxel-loaded liposomes, prodrugs, cyclodextrins, and peptide–taxane conjugates. Moreover, the review also covers various delivery routes of conventional paclitaxel or novel paclitaxel formulations, such as oral administration, local applications, and intraperitoneal delivery.
Conclusion
In addition to albumin-bound paclitaxel, polymeric micelles appear to be the most promising formulations for innovative drug delivery systems at present. A variety of variants of polymeric micelles are currently undergoing advanced phases of clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Technology, Nicolaus Copernicus University in Torun, Ludwik Rydygier Collegium Medicum, Bydgoszcz, Poland.
- Central Cytostatic Drug Department, Hospital Pharmacy, The F. Lukaszczyk Oncology Centre, Bydgoszcz, Poland.
- Department of Oncology and Brachytherapy, Nicolaus Copernicus University in Torun, Ludwik Rydygier Collegium Medicum, Bydgoszcz, Poland.
- Department of Oncology, Franciszek Lukaszczyk Oncology Centre, Bydgoszcz, Poland.
- Department of Neurosurgery, 10th Military Research Hospital and Polyclinic, Bydgoszcz, Poland.
- Department of Clinical Oncology, and Nursing, Department of Oncological Surgery, Nicolaus Copernicus University in Torun, Ludwik Rydygier Collegium Medicum, Bydgoszcz, Poland.
ORCID-Profile: Krzysztof Koper
Zitieren
APA
Wileński, S., Koper, A., Śledzińska, P., Bebyn, M., & Koper, K. (2024). Innovative strategies for effective paclitaxel delivery: Recent developments and prospects. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552231208978
Vancouver
Wileński S, Koper A, Śledzińska P, Bebyn M, Koper K. Innovative strategies for effective paclitaxel delivery: Recent developments and prospects. Journal of Oncology Pharmacy Practice. 2024. doi:10.1177/10781552231208978
BibTeX
@article{Wileski2024,
author = {Wileński, Sławomir and Koper, Agnieszka and Śledzińska, Paulina and Bebyn, Marek and Koper, Krzysztof},
title = {Innovative strategies for effective paclitaxel delivery: Recent developments and prospects},
journal = {Journal of Oncology Pharmacy Practice},
year = {2024},
doi = {10.1177/10781552231208978}
}
EUVIMED